Clinical Report: Top 10 Evidence-Based Essentials in Dermatology

Overview

This report summarizes the top 10 evidence-based essentials guiding dermatologic care, including updated guidelines for acne, atopic dermatitis, and psoriasis. Key clinical trials and validated severity instruments underpin current therapeutic recommendations and treatment strategies.

Background

Dermatology practice relies heavily on clinical guidelines, pivotal trial data, targeted therapies, and validated severity assessment tools. The American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) provide updated guidelines reflecting recent evidence and novel therapies. Severity indices such as PASI and EASI are integral to clinical trials and research. This framework highlights the most impactful evidence-based resources shaping dermatologic management.

Data Highlights

Key Findings

• The 2024 AAD Acne Guideline strongly recommends benzoyl peroxide, topical retinoids, topical antibiotics, oral doxycycline, and oral isotretinoin for acne vulgaris management.
• Updated AAD adult atopic dermatitis guidelines (2023-2025) incorporate novel therapies including JAK inhibitors and topical ruxolitinib cream.
• The Joint AAD-NPF psoriasis guideline covers comprehensive management including topical, biologic, systemic nonbiologic therapies, phototherapy, and pediatric psoriasis.
• Phase 3 POETYK PSO-2 trial demonstrated deucravacitinib's superiority over placebo in moderate to severe plaque psoriasis at 16 weeks.
• ARCADIA 1 and 2 trials showed nemolizumab plus topical therapy effectively reduces inflammation and itch in moderate-to-severe atopic dermatitis.
• Meta-analysis identified brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa as biologics with highest PASI response rates in psoriasis.

Clinical Implications

Clinicians should incorporate updated AAD guidelines and recent trial evidence when selecting therapies for acne, atopic dermatitis, and psoriasis. The use of targeted biologics and JAK inhibitors has expanded treatment options for moderate-to-severe disease. Severity instruments like PASI and EASI remain essential for clinical trials but are less emphasized in routine practice.

Conclusion

The top 10 evidence-based essentials in dermatology provide a robust framework integrating guideline recommendations, clinical trial data, and validated assessment tools to optimize patient care. Ongoing updates reflect evolving therapeutic landscapes and support informed clinical decision-making.

References

1. American Academy of Dermatology Association -- Acne and Atopic Dermatitis Guidelines 2023-2025
2. National Psoriasis Foundation & AAD -- Joint Psoriasis Guideline
3. POETYK PSO-2 Trial -- Deucravacitinib in Plaque Psoriasis
4. ARCADIA 1 and 2 Trials -- Nemolizumab in Atopic Dermatitis
5. JAMA Dermatology Meta-analysis -- Biologics for Psoriasis
6. Harmonising Outcome Measures for Eczema -- EASI Instrument